The debate over an abbreviated biologics pathway took a big step forward with the Food & Drug Administration’s approval of Sandoz ’ recombinant human growth hormone Omnitrope. The approval itself is precedent setting, but the bigger ramifications are political: the action steps up the pressure on Congress to address the issue head-on.
FDA cleared somatropin (Omnitrope) for marketing in the US on May 30 under the 505(b)(2) regulatory pathway, which allows sponsors...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?